Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 478793, 6 pages
http://dx.doi.org/10.1155/2015/478793
Research Article

The Value of Safflower Yellow Injection for the Treatment of Acute Cerebral Infarction: A Randomized Controlled Trial

1Department of Neurology, Affiliated Lianyungang Hospital of Nanjing University of Chinese Medicine, No. 160 W. Chaoyang Road, Lianyungang 222000, China
2Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013, USA
3Changchun Sanzhen Industry Co., Ltd., Changchun 130000, China

Received 8 August 2014; Revised 21 September 2014; Accepted 6 October 2014

Academic Editor: Feng-Qing Yang

Copyright © 2015 Le-Jun Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Medicine, vol. 3, no. 11, article e442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. D. A. Wolfe, “The impact of stroke,” British Medical Bulletin, vol. 56, no. 2, pp. 275–286, 2000. View at Google Scholar · View at Scopus
  3. Z. F. Yang, Q. B. Mei, and Y. P. Jiang, “The effective components and pharmacological effects of safflower,” Xi Bei Yao Xue Za Zhi, vol. 16, no. 2, pp. 131–133, 2001 (Chinese). View at Google Scholar
  4. S. Fan, N. Lin, G. Shan, P. Zuo, and L. Cui, “Safflower yellow for acute ischemic stroke: a systematic review of randomized controlled trials,” Complementary Therapies in Medicine, vol. 22, no. 2, pp. 354–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. B.-X. Zang, M. Jin, N. Si, Y. Zhang, W. Wu, and Y.-Z. Piao, “Antagonistic effect of hydroxysafflor yellow a on the platelet activating factor receptor,” Yaoxue Xuebao, vol. 37, no. 9, pp. 696–699, 2002 (Chinese). View at Google Scholar · View at Scopus
  6. H. B. Zhu, L. Zhang, Z. H. Wang et al., “Therapeutic effects of hydroxysafflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms,” Journal of Asian Natural Products Research, vol. 7, no. 4, pp. 607–613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Sun, X. Wei, S. Qu, Y. Zhao, and X. Zhang, “Hydroxysafflor yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats,” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 14, pp. 4120–4124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Sun, L. Yang, Y.-W. Xu et al., “Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and bloodbrain barrier disruption,” Brain Research, vol. 1473, no. 9, pp. 227–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S.-Y. Ye and W.-Y. Gao, “Hydroxysafflor yellow a protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats,” Archives of Pharmacal Research, vol. 31, no. 8, pp. 1010–1015, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-W. Tian, F.-H. Fu, W.-L. Jiang, C.-Y. Wang, F. Sun, and T.-P. Zhang, “Protective effect of hydroxysafflor yellow A against rat cortex mitochondrial injuries induced by cerebral ischemia,” Yaoxue Xuebao, vol. 39, no. 10, pp. 774–777, 2004 (Chinese). View at Google Scholar · View at Scopus
  11. Z. L. Ma, B. X. Wu, D. M. Cheng et al., “Clinic observation of the curative effect of saffbr yellow in the treatment of acute cerebral infarction,” Chinese Journal of Practical Nervous Disease, vol. 14, no. 24, pp. 30–31, 2011 (Chinese). View at Google Scholar
  12. B. Ye, W. J. Li, L. Zheng, and R. Liu, “Effect of safflower yellow pigment on blood rheology and cerebral hemodynamics in patients with acute cerebral infarction,” Chinese Journal of General Practice, vol. 10, no. 2, pp. 219–221, 2012 (Chinese). View at Google Scholar
  13. B. Wu, M. Liu, H. Liu et al., “Meta-analysis of traditional Chinese patent medicine for ischemic stroke,” Stroke, vol. 38, no. 6, pp. 1973–1979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Chinese Neuroscience Society and Chinese Neurosurgical Society, “Diagnostic criteria of various types of cerebrovascular disease,” Zhong Hua Shen Jing Ke Za Zhi, vol. 29, no. 6, pp. 89–90, 1996 (Chinese). View at Google Scholar
  15. J. Wu, J. P. Jia, and L. Y. Cui, Neurology, People's Health Publishing Company, Beijing, China, 2005, (Chinese).
  16. L. B. Goldstein and G. P. Samsa, “Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial,” Stroke, vol. 28, no. 2, pp. 307–310, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Bruno, J. P. McConnell, S. N. Cohen et al., “Serial urinary 11-dehydrothromboxane B2 , aspirin dose, and vascular events in blacks after recent cerebral infarction,” Stroke, vol. 35, no. 3, pp. 727–730, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Velcheva, E. Titianova, and N. Antonova, “Evaluation of the hemorheological and neurosonographic relationship in patients with cerebrovascular diseases,” Clinical Hemorheology and Microcirculation, vol. 30, no. 3-4, pp. 373–380, 2004. View at Google Scholar · View at Scopus
  19. W. Wu, M. Jin, and S. D. Yang, “Safflower yellow inhibition of platelet-activating factor due to the proliferation of capillary permeability,” Cardiopulmonary Disease Journal, vol. 18, no. 4, pp. 281–283, 1999. View at Google Scholar
  20. W. M. Kuebler, Y. Yang, R. Samapati, and S. Uhlig, “Vascular barrier regulation by PAF, ceramide, caveolae, and NO-an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature,” Cellular Physiology and Biochemistry, vol. 26, no. 1, pp. 29–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. W. Li, “Safflower yellow plasminogen activator inhibiting agents dose levels in rabbit,” Chinese Herbal Medicine, vol. 30, no. 2, pp. 128–129, 1999 (Chinese). View at Google Scholar
  22. T. Sairanen, O. Carpén, M.-L. Karjalainen-Lindsberg et al., “Evolution of cerebral tumor necrosis factor-α production during human ischemic stroke,” Stroke, vol. 32, no. 8, pp. 1750–1757, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. H. S. Han and M. A. Yenari, “Cellular targets of brain inflammation in stroke,” Current Opinion in Investigational Drugs, vol. 4, no. 5, pp. 522–529, 2003. View at Google Scholar · View at Scopus
  24. A. Durukan and T. Tatlisumak, “Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia,” Pharmacology Biochemistry and Behavior, vol. 87, no. 1, pp. 179–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Allan and N. J. Rothwell, “Cytokines and acute neurodegeneration,” Nature Reviews Neuroscience, vol. 2, no. 10, pp. 734–744, 2001. View at Publisher · View at Google Scholar · View at Scopus